No trade signal. This is a standard employee compensation grant with no immediate financial or strategic implications. Monitor next quarterly filing for any changes in outstanding share count from ongoing equity programs.
Price Chart
Executive Summary
Genmab A/S filed a 6-K reporting a routine grant of 15,894 restricted stock units and 15,494 warrants to employees. The grants are standard long-term incentive compensation with 3-year vesting, representing a minimal and immaterial dilution relative to the company's $15.7B market cap.
Key Facts
- Grant of 15,894 restricted stock units and 15,494 warrants to employees on June 11, 2026.
- RSU fair value of DKK 1,616.50 per unit (closing price on grant date); warrant fair value of DKK 534.23 per warrant (Black-Scholes).
- Both instruments vest three years from grant date; warrants expire at the seventh anniversary.
- The awards are cost-free to recipients; exercise price per warrant is DKK 1,616.50.
- Total potential dilution is negligible relative to Genmab's outstanding share count (~$15.7B market cap).
Financial Impact
Immaterial — combined fair value of roughly DKK 33.9M (~$4.8M) based on RSU fair value of ~DKK 25.7M and warrant fair value of ~DKK 8.3M; this is less than 0.03% of market cap.
Risk Factors
- None from this filing; equity compensation programs are routine for a biotech company.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001434265-26-000087 |
| Document: gmab_20260611xx6k.htm | 0001434265-26-000087 |
| Document: 0001434265-26-000087-index-headers.html | 0001434265-26-000087 |
| Document: 0001434265-26-000087-index.html | 0001434265-26-000087 |
| Document: 0001434265-26-000087.txt | 0001434265-26-000087 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 8, 2026 24d ago | 6-K | $33.53 $32.65 | ▼ −2.62% | ▼ −1.96% | $34.49 (+2.85%) |
Aug 12, 2026 7w ago | 6-K | $31.42 $34.11 | ▲ +8.56% | ▲ +9.01% | $34.49 (+9.75%) |
Aug 11, 2026 7w ago | 6-K | $30.85 $32.96 | ▲ +6.84% | ▲ +7.24% | $34.49 (+11.78%) |
Aug 6, 2026 8w ago | 6-K | $29.83 $31.34 | ▲ +5.06% | ▲ +3.85% | $34.49 (+15.61%) |
Jul 15, 2026 11w ago | 6-K | $29.08 $28.85 | ▼ −0.79% | ▲ +0.19% | $34.49 (+18.59%) |
Jun 29, 2026 13w ago | 6-K | $27.47 $28.01 | ▲ +1.97% | ▲ +1.36% | $34.49 (+25.54%) |
Jun 17, 2026 15w ago | 6-K | $25.39 $25.87 | ▲ +1.87% | ▲ +2.91% | $34.49 (+35.82%) |
Jun 16, 2026 15w ago | 6-K | $24.74 $25.94 | ▲ +4.85% | ▲ +7.08% | $34.49 (+39.39%) |
Jun 15, 2026 15w ago | 6-K | $24.58 $25.61 | ▲ +4.19% | ▲ +5.57% | $34.49 (+40.30%) |
Jun 15, 2026 15w ago | 6-K | $24.58 $25.61 | ▲ +4.19% | ▲ +5.57% | $34.49 (+40.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access